ARID1A and neoplasm: After in-depth analysis and in vivo verification, they found that the lack of ARID1A heterozygosity in GC will lead to the extensive loss of H3K27ac modification in the enhancer region of genes related to TP53 tumor suppressor pathway and apoptosis pathway, resulting in the inhibition of p53 apoptosis-related gene expression, thereby promoting tumor progression.